NEPHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

NEPHROS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026

$3.68+0.03 (+0.82%)

Close on Oct 19, 2026

Market cap: $40.89M
P/E (TTM): 23.0
Dividend yield: –

Dividends

Nephros has not reported a dividend

No dividend per share appears in Nephros's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in Nephros's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-9 reverse split on Aug 7, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is NEPH.

Revenue growth24.2% · median 22.4%

Gross margin61.3% · median 60.2%

Operating margin7.9% · median -5.0%

Net margin8.4% · median -10.3%

Company	Revenue	Growth
KRMD	$45.11M	+22.4%
CTSO	$37.22M	+3.1%
UTMD	$36.11M	–
SNOA	$21.92M	+47.0%
NEPH	$20.72M	+24.2%
BDMD	–	–

Company

Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 36
Held by institutions: 48.9%
Auditor: Baker Tilly US, LLP
SEC CIK: 1196298

Advertisement
300 × 250